Report
Jason Kalamboussis ...
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Thomas Couvreur

Morning Note: BINCK NA, UCB BB

BinckBank: 1H results
UCB: Cimzia approved for arthritis in China
Underlyings
BinckBank N.V.

BinckBank is a full-service online bank for investors in Europe. Co. provides a comprehensive, user-friendly website that allows private investors to invest anywhere in the world at competitive rates. The Retail business unit services private investors under the brands Alex and Binck. Binck's services are for the active and experienced independent investor, while Alex is for the private investor who wants to get more out of his assets. In addition to serving private investors, Co. serves approximately 100 professional parties. The Professional Services business unit serves independent investment managers, banks, insurance companies and pension administrators in the Netherlands and Belgium.

UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jason Kalamboussis

Lenny Van Steenhuyse

Sandra Cauwenberghs

Thomas Couvreur

Other Reports on these Companies
Other Reports from KBC Securities
Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thomas Couvreur
  • Wim Lewi
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Thomas Vranken
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch